Soon-Shiong P - Search Results

1

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.

Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C. Lee MY, et al. J Immunother Cancer. 2021 Mar;9(3):e002128. doi: 10.1136/jitc-2020-002128. J Immunother Cancer. 2021. PMID: 33741731 Free PMC article.

2

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.

Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM 2nd, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J. Jochems C, et al. Oncotarget. 2016 Dec 27;7(52):86359-86373. doi: 10.18632/oncotarget.13411. Oncotarget. 2016. PMID: 27861156 Free PMC article.

3

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31^stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.

Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS. Adusumilli PS, et al. J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. J Immunother Cancer. 2017. PMID: 28649381 Free PMC article. Review.

4

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).

Jochems C, Tritsch SR, Pellom ST, Su Z, Soon-Shiong P, Wong HC, Gulley JL, Schlom J. Jochems C, et al. Oncotarget. 2017 Sep 8;8(43):75217-75231. doi: 10.18632/oncotarget.20680. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088859 Free PMC article.

5

Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.

Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW. Fenerty KE, et al. J Immunother Cancer. 2018 Nov 29;6(1):133. doi: 10.1186/s40425-018-0445-4. J Immunother Cancer. 2018. PMID: 30486888 Free PMC article.

6

The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex.

Jochems C, Tritsch SR, Knudson KM, Gameiro SR, Smalley Rumfield C, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J. Jochems C, et al. Oncoimmunology. 2018 Nov 27;8(2):e1532764. doi: 10.1080/2162402X.2018.1532764. eCollection 2019. Oncoimmunology. 2018. PMID: 30713787 Free PMC article.

7

Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.

Lee KL, Benz SC, Hicks KC, Nguyen A, Gameiro SR, Palena C, Sanborn JZ, Su Z, Ordentlich P, Rohlin L, Lee JH, Rabizadeh S, Soon-Shiong P, Niazi K, Schlom J, Hamilton DH. Lee KL, et al. Cancer Immunol Res. 2019 Aug;7(8):1359-1370. doi: 10.1158/2326-6066.CIR-18-0620. Epub 2019 Jul 10. Cancer Immunol Res. 2019. PMID: 31292145 Free PMC article.

8

Correction to: Immunotherapy Utilizing the Combination of Natural Killer- and Antibody Dependent Cellular Cytotoxicity (ADCC)-Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition.

Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW. Fenerty KE, et al. J Immunother Cancer. 2019 Sep 2;7(1):234. doi: 10.1186/s40425-019-0715-9. J Immunother Cancer. 2019. PMID: 31477176 Free PMC article.

9

Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.

Giles AJ, Hao S, Padget M, Song H, Zhang W, Lynes J, Sanchez V, Liu Y, Jung J, Cao X, Fujii R, Jensen R, Gillespie D, Schlom J, Gilbert MR, Nduom EK, Yang C, Lee JH, Soon-Shiong P, Hodge JW, Park DM. Giles AJ, et al. JCI Insight. 2019 Oct 17;4(20):e130688. doi: 10.1172/jci.insight.130688. JCI Insight. 2019. PMID: 31536478 Free PMC article.

10

Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.

Hicks KC, Knudson KM, Lee KL, Hamilton DH, Hodge JW, Figg WD, Ordentlich P, Jones FR, Rabizadeh S, Soon-Shiong P, Schlom J, Gameiro SR. Hicks KC, et al. Clin Cancer Res. 2020 Feb 1;26(3):704-716. doi: 10.1158/1078-0432.CCR-19-0727. Epub 2019 Oct 23. Clin Cancer Res. 2020. PMID: 31645354 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

128 results

Search Page